AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19833276 — intervention group
Group type: COMPARATOR
Intervention: Group C (0.1 mL/kg of 0.9% NaCl pretreatment, slow rocuronium injection)
Number of subjects: 150
Study 19833276 — intervention group
Group type: EXPERIMENTAL
Intervention: Group L vs Group R
Number of subjects: 150
Study 17076848 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-assessment of bleeding symptoms
Number of subjects: 35
Study 17076848 — intervention group
Group type: COMPARATOR
Intervention: Study assessor assessment of bleeding symptoms
Number of subjects: 35
Study 17076848 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-assessment
Number of subjects: 35
Study 15283899 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of finasteride daily for 7 years
Number of subjects: 0
Study 11408340 — intervention group
Group type: EXPERIMENTAL
Intervention: CuZn-superoxide dismutase (CuZn-SOD) in CSF from ALS patients with D90A mutation
Number of subjects: 113
Study 11408340 — intervention group
Group type: COMPARATOR
Intervention: CuZn-superoxide dismutase (CuZn-SOD) in CSF from ALS patients without CuZn-SOD mutations
Number of subjects: 113
Study 11408340 — intervention group
Group type: COMPARATOR
Intervention: CuZn-superoxide dismutase (CuZn-SOD) in CSF from controls
Number of subjects: 113
Study 11408340 — intervention group
Group type: EXPERIMENTAL
Intervention: CuZn-superoxide dismutase (CuZn-SOD) in CSF from D90A homozygous ALS patients
Number of subjects: 113
Study 11408340 — intervention group
Group type: COMPARATOR
Intervention: Extracellular SOD in CSF
Number of subjects: 113
Study 9252801 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone (200 mg)
Number of subjects: 16
Study 9252801 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone with standard-release levodopa/benserazide formulations (50/12.5 mg, 100/25 mg, 200/50 mg)
Number of subjects: 16
Study 9252801 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone with controlled-release levodopa/benserazide formulation (100/25 mg)
Number of subjects: 16
Study 9252801 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 16
Study 9252801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8060907 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy-treatment
Number of subjects: 68
Study 8060907 — intervention group
Group type: EXPERIMENTAL
Intervention: Facts-treatment
Number of subjects: 68
Study 8060907 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 68
Study 3565001 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium intake of 2 mmol/kg/day (sodium chloride)
Number of subjects: 20
Study 3565001 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium intake of 4 mmol/kg/day (sodium chloride and acetate)
Number of subjects: 20
Study 29240541 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastasis-directed therapy (MDT)
Number of subjects: 62
Study 29240541 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 62
Study 26763773 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg once daily
Number of subjects: 73
Study 26763773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 24227806 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 32
Study 24227806 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 32
Study 22647783 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 207
Study 22647783 — intervention group
Group type: COMPARATOR
Intervention: Azelnidipine
Number of subjects: 207
Study 20029208 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily placebo with pantoprazole rescue (n = 141)
Number of subjects: 203
Study 20029208 — intervention group
Group type: COMPARATOR
Intervention: Daily pantoprazole with placebo rescue (n = 62)
Number of subjects: 203
Study 18533208 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided-tissue regeneration (GTR) with deproteinized bovine bone and resorbable collagen membrane
Number of subjects: 55
Study 18533208 — intervention group
Group type: COMPARATOR
Intervention: No GTR (control group)
Number of subjects: 55
Study 16500168 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric somatosensory stimulation applied to the paretic hand
Number of subjects: 9
Study 16500168 — intervention group
Group type: COMPARATOR
Intervention: Electric somatosensory stimulation applied to the paretic leg
Number of subjects: 9
Study 16500168 — intervention group
Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 9
Study 15485731 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 3000
Study 15485731 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 3000
Study 15485731 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-benefit acceptability curve
Number of subjects: 3000
Study 15485731 — intervention group
Group type: EXPERIMENTAL
Intervention: Net-benefit curve
Number of subjects: 3000
Study 11001344 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (15 min of cycle ergometry at 60% V(O2max) followed by 30 min of recovery)
Number of subjects: 6
Study 11001344 — intervention group
Group type: COMPARATOR
Intervention: Control (remained seated with no exercise for 45 min)
Number of subjects: 6
Study 9432219 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of alcohol to the finger before the puncture
Number of subjects: 300
Study 9432219 — intervention group
Group type: COMPARATOR
Intervention: No application of alcohol to the finger before the puncture
Number of subjects: 300
Study 9432219 — intervention group
Group type: COMPARATOR
Intervention: Another intervention group (not specified)
Number of subjects: 300
Study 8249851 — intervention group
Group type: EXPERIMENTAL
Intervention: ACIP protocol
Number of subjects: 44
Study 8249851 — intervention group
Group type: COMPARATOR
Intervention: Bruce protocol
Number of subjects: 44
Study 8249851 — intervention group
Group type: EXPERIMENTAL
Intervention: ACIP and modified ACIP protocols
Number of subjects: 44
Study 8249851 — intervention group
Group type: COMPARATOR
Intervention: Bruce and Cornell protocols
Number of subjects: 44
Study 8249851 — intervention group
Group type: EXPERIMENTAL
Intervention: All four protocols
Number of subjects: 44
Study 8249851 — intervention group
Group type: EXPERIMENTAL
Intervention: ACIP, modified ACIP, Cornell protocols
Number of subjects: 44
Study 3920861 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Sorbinil
Number of subjects: 37
Study 3920861 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg Sorbinil
Number of subjects: 37
Study 3920861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 29986690 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Group Conferencing (FGC)
Number of subjects: 69
Study 29986690 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 69
Study 29986690 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Group Conferencing (FGC) for families who refused FGC
Number of subjects: 69
Study 29986690 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Group Conferencing (FGC) for families that prepared or completed FGC
Number of subjects: 69
Study 27184219 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-hour lecture
Number of subjects: 727
Study 27184219 — intervention group
Group type: COMPARATOR
Intervention: Seven-hour series of lectures
Number of subjects: 727
Study 27184219 — intervention group
Group type: COMPARATOR
Intervention: Four-hour series with a friend or close relative
Number of subjects: 727
Study 25265777 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin generic form (GGF)
Number of subjects: 41
Study 25265777 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin original form (GOF)
Number of subjects: 41
Study 25265777 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 22432521 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoPen® 5 (NP5)
Number of subjects: 0
Study 22432521 — intervention group
Group type: COMPARATOR
Intervention: HumaPen® Memoir™ (HPM)
Number of subjects: 0
Study 22432521 — intervention group
Group type: COMPARATOR
Intervention: HumaPen Luxura® (HPL)
Number of subjects: 0
Study 22432521 — intervention group
Group type: COMPARATOR
Intervention: ClikSTAR® (CS)
Number of subjects: 0
Study 20589494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 200 mg/day
Number of subjects: 9
Study 20589494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 800 mg/day
Number of subjects: 9
Study 20589494 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (1.5, 3.0, and 6.0 mg)
Number of subjects: 9
Study 20589494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 18765698 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous antiretroviral therapy
Number of subjects: 5472
Study 18765698 — intervention group
Group type: COMPARATOR
Intervention: Episodic antiretroviral therapy
Number of subjects: 5472
Study 15699233 — intervention group
Group type: COMPARATOR
Intervention: Choline-fed mice (10 or 35 mmol choline/kg diet)
Number of subjects: 8
Study 15699233 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline-deficient mice (0 mmol choline/kg diet)
Number of subjects: 8
Study 15699233 — intervention group
Group type: COMPARATOR
Intervention: Men not choline depleted (550 mg choline/d)
Number of subjects: 8
Study 15699233 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically choline-depleted men (low choline diet)
Number of subjects: 8
Study 12964912 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation with an alternative health practitioner
Number of subjects: 41477
Study 12964912 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM users
Number of subjects: 41477
Study 12964912 — intervention group
Group type: COMPARATOR
Intervention: CAM non-users
Number of subjects: 41477
Study 10690245 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg) + Ivermectin (200 micrograms/kg)
Number of subjects: 155
Study 10690245 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg) + DEC (6 mg/kg)
Number of subjects: 155
Study 10690245 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (400 mg) alone
Number of subjects: 155
Study 8699911 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pilocarpine (candy-like pastille) administered in increasing dosages for 5 weeks
Number of subjects: 40
Study 8699911 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pilocarpine (candy-like pastille)
Number of subjects: 40
Study 8699911 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pilocarpine administration
Number of subjects: 40
Study 1873372 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mcg selenium daily for 5 weeks
Number of subjects: 50
Study 1873372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6850722 — intervention group
Group type: EXPERIMENTAL
Intervention: guanadrel sulfate
Number of subjects: 18
Study 6850722 — intervention group
Group type: COMPARATOR
Intervention: guanethidine sulfate
Number of subjects: 18
Study 6850722 — intervention group
Group type: EXPERIMENTAL
Intervention: guanadrel sulfate and guanethidine sulfate
Number of subjects: 18
Study 31815649 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg daily
Number of subjects: 661
Study 31815649 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg daily
Number of subjects: 661
Study 31815649 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (both doses)
Number of subjects: 661
Study 31815649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 661
Study 29182407 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (conventional anti-diabetic doses)
Number of subjects: 65
Study 29182407 — intervention group
Group type: COMPARATOR
Intervention: Control (non-treatment mixed)
Number of subjects: 65
Study 27516139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaderm™ CHG dressing
Number of subjects: 59
Study 27516139 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 59
Study 24799181 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL photodynamic therapy (PDT) with vaginal suppository, 5 hours before illumination with 50 J/cm² red coherent light (633 nm)
Number of subjects: 70
Study 24799181 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal suppository
Number of subjects: 70
Study 24799181 — intervention group
Group type: COMPARATOR
Intervention: Follow-up only
Number of subjects: 70
Study 24799181 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL photodynamic therapy (PDT)
Number of subjects: 70
Study 24799181 — intervention group
Group type: COMPARATOR
Intervention: Placebo PDT
Number of subjects: 70
Study 24799181 — intervention group
Group type: COMPARATOR
Intervention: Follow-up group
Number of subjects: 70
Study 22336284 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ‐ 40 newtons cricoid pressure
Number of subjects: 212
Study 22336284 — intervention group
Group type: COMPARATOR
Intervention: unmeasured cricoid pressure (control)
Number of subjects: 212
Study 19894215 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 85
Study 19894215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 19039880 — intervention group
Group type: EXPERIMENTAL
Intervention: Household-based lifestyle intervention
Number of subjects: 57
Study 15876944 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg/d for 3 days weekly, for 3 weeks) with symptom-specific agents
Number of subjects: 352
Study 15876944 — intervention group
Group type: COMPARATOR
Intervention: Symptom-specific agents alone
Number of subjects: 352
Study 12472171 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 20
Study 12472171 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 20
Study 9498512 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU/kg intravenous EPO three times weekly
Number of subjects: 19
Study 9498512 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 19
Study 7611589 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms, four times a day)
Number of subjects: 8843
Study 7611589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8843
Study 7611589 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 8843
Study 1978371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsapirone 15 mg
Number of subjects: 0
Study 1978371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsapirone 30 mg
Number of subjects: 0
Study 1978371 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 15 mg
Number of subjects: 0
Study 1978371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 389346 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal dilatation
Number of subjects: 216
Study 389346 — intervention group
Group type: COMPARATOR
Intervention: Sphincterotomy
Number of subjects: 216
Study 389346 — intervention group
Group type: COMPARATOR
Intervention: High-fibre diet
Number of subjects: 216
Study 389346 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber-band ligation
Number of subjects: 216
Study 389346 — intervention group
Group type: COMPARATOR
Intervention: Cryosurgery
Number of subjects: 216
Study 389346 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 216
Study 30448183 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 90
Study 30448183 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS)
Number of subjects: 90
Study 30448183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 29178943 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF) at a dose of 70 ml/kg/hour for 48 hours
Number of subjects: 28
Study 29178943 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF)
Number of subjects: 28
Study 29178943 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard management)
Number of subjects: 28
Study 25923551 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including audits of indications for cesarean delivery, feedback to health professionals, and implementation of best practices.
Number of subjects: 184952
Study 25923551 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 184952
Study 25923551 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 184952
Study 23619733 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision TKA in patients with BMI < 30 kg/m2
Number of subjects: 75
Study 23619733 — intervention group
Group type: COMPARATOR
Intervention: Revision TKA in patients with BMI ≥ 30 kg/m2
Number of subjects: 75
Study 22168642 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 86
Study 19134020 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Bifidobacterium longum (BL999) 1 x 10(7) CFU/g and Lactobacillus rhamnosus (LPR) 2 x 10(7) CFU/g)
Number of subjects: 253
Study 19134020 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 253
Study 17343738 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist heart failure nurse care plus a nurse-led predominantly home-based exercise intervention
Number of subjects: 169
Study 17343738 — intervention group
Group type: COMPARATOR
Intervention: Specialist heart failure nurse care alone
Number of subjects: 169
Study 15083363 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude exposure (15-20 days at 5,050 m)
Number of subjects: 12
Study 11642024 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (23 F per gram) in continuous infusion through a central venous catheter
Number of subjects: 30
Study 11642024 — intervention group
Group type: COMPARATOR
Intervention: Teicoplanin (311‐357 F a 400 mg vial) intramuscularly
Number of subjects: 30
Study 9527806 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Number of subjects: 0
Study 9527806 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 0
Study 8050692 — intervention group
Group type: EXPERIMENTAL
Intervention: Heating of CO2 gas to 37 degrees C during insufflation
Number of subjects: 0
Study 3058475 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1‐1.5 mg kg‐1 body weight
Number of subjects: 30
Study 3058475 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone 0.75‐1 mg kg‐1 body weight
Number of subjects: 30
Study 3058475 — intervention group
Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 30
Study 29349919 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone calls to schedule next consultation a week in advance (Group A)
Number of subjects: 116
Study 29349919 — intervention group
Group type: COMPARATOR
Intervention: Scheduling next appointment at the end of each visit (Group B)
Number of subjects: 116
Study 27639100 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of urinary free cortisol (UFC), DHEAs, IGF‐I and lower free T4 in women
Number of subjects: 383
Study 27639100 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher urinary free cortisol (UFC) concentration in women
Number of subjects: 383
Study 27639100 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher testosterone in men
Number of subjects: 383
Study 27639100 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher IGF‐I concentration in men
Number of subjects: 383
Study 27639100 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 383
Study 24253484 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 60 mg daily
Number of subjects: 34
Study 24253484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 24253484 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 34
Study 23860961 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (0.4 μg/kg/day) in 100 ml sterile saline
Number of subjects: 370
Study 23860961 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline (control group)
Number of subjects: 370
Study 19243750 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mug of misoprostol (n = 25)
Number of subjects: 52
Study 19243750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 27)
Number of subjects: 52
Study 19243750 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mug of misoprostol (n = 13, subgroup 1)
Number of subjects: 52
Study 19243750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12, subgroup 1)
Number of subjects: 52
Study 19243750 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mug of misoprostol (n = 15, subgroup 2)
Number of subjects: 52
Study 19243750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12, subgroup 2)
Number of subjects: 52
Study 18835071 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic trapezius myalgia
Number of subjects: 62
Study 18835071 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 62
Study 16623075 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ 150/12.5 mg (8 weeks)
Number of subjects: 825
Study 16623075 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ 300/25 mg (8 weeks)
Number of subjects: 825
Study 16623075 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ treatment
Number of subjects: 825
Study 12794569 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback with anal manometry
Number of subjects: 120
Study 12794569 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback with transanal ultrasound
Number of subjects: 120
Study 12794569 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor exercises with feedback from digital examination alone
Number of subjects: 120
Study 11336155 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal meal feeding (liquid meal at 2 kcal/2 ml/min)
Number of subjects: 15
Study 11336155 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 15
Study 9180659 — intervention group
Group type: EXPERIMENTAL
Intervention: Restraint education with consultation (REC)
Number of subjects: 643